Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant

Transplant International

Volumn 28, Issue 4, 2015, Pages 502-

  Mancuso, Andrea ^a,b   Perricone, Giovanni ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b ARNAS General Hospital Civico di Cristina e Benfratelli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

CANCER RECURRENCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER CELL CARCINOMA; LIVER GRAFT; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; ANALOGS AND DERIVATIVES; FEMALE; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; PROCEDURES;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS;

EID: 84926356602     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12477     Document Type: Letter

References (7)

1. Cholongitas E, Mamou C, Rodriguez-Castro KI, et al,. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039.
2. Liang W, Wang D, Ling X, et al,. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18: 62.
3. Menon KV, Hakeem AR, Heaton ND,. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411.
4. Zhu A, Kudo M, Assenat E, et al,. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib. The EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57.
5. Mancuso A, Airoldi A, Vigano R, et al,. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Dig Liver Dis 2011; 43: 754.
6. Gomez-Martin C, Bustamante J, Castroagudin JF, et al,. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012; 18: 45.
7. Sotiropoulos GC, Nowak KW, Fouzas I, et al,. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Transplant Proc 2012; 44: 2754.